(INTS)
NCM – Real Time Price. Currency in USD
6.03
-0.07 (-1.15%)
At close: Mar 27, 2026, 4:00 PM EDT
6.04
+0.01 (0.17%)
After-hours: Mar 27, 2026, 7:21 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
6.03
-0.07 (-1.15%)
At close: Mar 27, 2026, 4:00 PM EDT
6.04
+0.01 (0.17%)
After-hours: Mar 27, 2026, 7:21 PM EDT
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
| Name | Position |
|---|---|
| Mr. James M. Ahlers | Executive Vice President of Corporate Finance |
| Mr. John Wesolowski CPA, M.B.A. | Principal Accounting Officer & Controller |
| Mr. Joseph Talamo CPA, M.B.A. | Chief Financial Officer |
| Mr. Lewis H. Bender M.A., M.B.A., M.S. | Founder, President, CEO & Chairman of the Board |
| Date | Type | Document |
|---|---|---|
| 2026-03-06 | 8-K | intensity-20260305.htm |
| 2026-03-05 | 8-K | intensity-20260305.htm |
| 2026-01-23 | S-8 | forms-8january2026.htm |
| 2025-12-05 | 8-K | intensity-20251204.htm |
| 2025-11-06 | 8-K | intensity-20251106.htm |
| 2025-10-31 | 8-K | intensity-20251030.htm |
| 2025-10-23 | 8-K | intensity-20251022.htm |
| 2025-09-10 | 8-K | intensity-20250910.htm |
| 2025-09-09 | DEFA14A | intensity-specialproxystat.htm |
| 2025-08-28 | PRE 14A | intensity-20250828.htm |